ARCHIVES

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Accepts Advisory Committee’s Recommendations On NDA, Labeling

October 26, 1979

In Brief: NCAB To Ponder Organ Systems Program Fate, Cancer Centers Issues, Hear Surveillance Review

January 29, 1988

NCI Calls Fisher “A Dominant Force” In Breast Cancer

September 5, 1997

DCPC Board Kills Cost Sharing for CIS, Rejects Primary Care Prevention Effort Evaluation Budget

May 13, 1988

In Brief: Broder Resigns From IVX; Bishop To Receive Public Service Award; Johnston Rejoins NIAID

August 7, 1998

Funding Opportunities.

April 5, 2002